{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu BY"],"funding":["U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)","U.S. Department of Health &amp; Human Services | NIH | U.S. National Library of Medicine","NIAID NIH HHS","U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)","NHGRI NIH HHS","NCI NIH HHS","NLM NIH HHS","NIH HHS"],"pagination":["82-91"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12285569"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(1)"],"pubmed_abstract":["Effective anti-tumor immunity is driven by cytotoxic CD8<sup>+</sup> T cells with specificity for tumor antigens. However, the factors that control successful tumor rejection are not well understood. Here we identify a subpopulation of CD8<sup>+</sup> T cells that are tumor-antigen-specific and can be identified by KIR expression but paradoxically impair anti-tumor immunity in patients with melanoma. These tumor-antigen-specific KIR<sup>+</sup>CD8<sup>+</sup> regulatory T cells target other tumor-antigen-specific CD8<sup>+</sup> T cells, can be detected in both the tumor and the blood, have a conserved transcriptional program and are associated with a poor overall survival. These findings broaden our understanding of the transcriptional and functional heterogeneity of human CD8<sup>+</sup>"],"journal":["Nature immunology"],"pubmed_title":["Circulating tumor-reactive KIR&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt; T cells suppress anti-tumor immunity in patients with melanoma."],"pmcid":["PMC12285569"],"funding_grant_id":["S10 OD030363","R01 CA269286","K12 CA215510","R01 CA121974","T32 CA233414","U24 AI11867","P30 CA016359","UM1 HG009390","T15 LM007056","P50 CA121974","R01 CA227473","K12 CA215110","P01 AI039671","R01 AI22220"],"pubmed_authors":["Lucca LE","Lu BY","Rayon-Estrada V","Hafler DA","Wei W","Zhang L","Wang J","Pham GH","Aizenbud L","Bacchiocchi A","Kojima ML","Obermair FJ","Nogueira CV","Clune J","Chiang V","Kluger Y","Heer S","Axisa PP","Kisielow J","Buitrago-Pocasangre NC","Olino K","Lewis W","Kluger HM","Halaban R","Walewski JJ","Coyle AJ","Reeves SM"],"additional_accession":[]},"is_claimable":false,"name":"Circulating tumor-reactive KIR&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt; T cells suppress anti-tumor immunity in patients with melanoma.","description":"Effective anti-tumor immunity is driven by cytotoxic CD8<sup>+</sup> T cells with specificity for tumor antigens. However, the factors that control successful tumor rejection are not well understood. Here we identify a subpopulation of CD8<sup>+</sup> T cells that are tumor-antigen-specific and can be identified by KIR expression but paradoxically impair anti-tumor immunity in patients with melanoma. These tumor-antigen-specific KIR<sup>+</sup>CD8<sup>+</sup> regulatory T cells target other tumor-antigen-specific CD8<sup>+</sup> T cells, can be detected in both the tumor and the blood, have a conserved transcriptional program and are associated with a poor overall survival. These findings broaden our understanding of the transcriptional and functional heterogeneity of human CD8<sup>+</sup>","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-03-15T17:56:06.85Z","creation":"2025-08-13T03:04:39.833Z"},"accession":"S-EPMC12285569","cross_references":{"pubmed":["39609626"],"doi":["10.1038/s41590-024-02023-4"]}}